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Other names: gp-340 (glycoprotein-340; human); 
SAG (salivary agglutinin; human); apactin (mouse); 
CRP-ductin (mouse); gp300 (glycoprotein 300; 
mouse); muclin (mouse); vomeroglandin (mouse); 
ebnerin (rat); hensin (rabbit); BGM (bovine gallbladder 
mucin, cattle); H3 (rhesus monkey) 
Location: 10q26.13 
Local order: between D10S1421 and D10S1273E. 
DNA/RNA 
Description 
The gene consists of 55 exons distributed over about 80  
kb. Scavenger receptor cysteine-rich (SRCR) domains 
are coded by single exons. Two small exons coding for 
serine-threonine-proline-rich stretches of 20-24 amino 
acids in length follow each SRCR exon. To these 
stretches it has been referred to as SRCR-interspersed 
domains (SIDs). The only exception is that there is only 
one of the two SID exons between SRCR4 and SRCR5. 
Transcription 
Longest transcript identified so far: 7656 bp including 
5'-utr, exons 1-16 and exons 18-54. Various alternaive 
transcripts with variable numbers of SRCR and SID 
exons exist. Exon 55 has not yet been verified to be 
present in human transcripts. 
Pseudogene 
No pseudogene known so far. 
 
Genomic organization of DMBT1. Top line: scale in kb. Second line: exon-intron structure of DMBT1 drawn to scale. Exons have the 
color code of the domains they are coding for. Exon 55 marked in black represents an exon with homology to the mouse and rat 
homologues, in which it codes for a transmembrane domain. Exon 55 has not yet been identified in a human transcript. Arrows depict 
regions, in which exon and intron sequences share high homologies. Bottom line: domain organization of the DMBT1 protein predicted 
from assembly of the first 54 exons. Entries to color codes and abbreviations are depicted in the section describing the protein. 
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Domain organization of DMBT1. Prototype: protein assembled from the first 54 exons (corresponding transcripts not yet identified). 
DMBT1/8kb.2: secreted DMBT1 variant encoded by the largest known transcript. DMBT1/6kb.1: secreted DMBT1 variant encoded by 
the smallest known transcript. Pink triangle: signal peptide putatively required for secretion; blue box repetitive motif of unknown 
function; red circles: scavenger receptor cysteine-rich (SRCR) domains; orange circles: SRCR-interspersed domains (SIDs); orange 
circles with TTT and STP: threonine- and serine-threonine-proline-rich domains with limited similarity to SIDs; CUB: C1r/C1s-Uegf-Bmp1 
domains; ZP: zona pellucida domain. 
Protein 
Description 
The largest known protein variant (DMBT1/8kb.2) 
comprises 2413 amino acids and has a calculated 
molecular weight of 265 kDa. Probably due to 
glycosylation the molecular weight of the purified 
protein is approximately 340 kDa. The smallest know 
variant (DMBT1/6kb.1), which lacks several SRCR 
domains and SIDs, comprises 1785 amino acids with a 
calculated molecular weight of 196 kDa. Various other 
protein variants lacking one or more SRCR domains 
may exist. The protein variants may arise due to genetic 
polymorphisms and/or alternative splicing. 
The SRCR domains are involved in ligand interactions. 
An 11 amino acid motif (GRVEVLYRGSW) present in 
each of the repeated SRCR domains has been shown to 
be responsible for the binding of a broad spectrum of 
Gram-positive and Gram-negative bacteria. The N-
terminal SRCR1/SD1 domain has been shown to 
interact with HIV gp120 and to suppress HIV infection. 
The functions of the CUB domains and of SRCR14, 
which shows only limited similarity to the other SRC  
domains within DMBT1, have not yet been determined. 
In other proteins, ZP domains have been shown to 
function in oligomerization. DMBT1 is also secreted as 
high molecular weight oligomers. 
SRCR, CUB, and ZP domains exclusively occur in 
multicellular animal organisms. 
Expression 
Main sites of DMBT1 expression are surface epithelial 
cells and associated glands, in particular in the 
respiratory and gastrointestinal tract. In most tissues 
low to moderate DMBT1 levels are expressed under 
normal conditions. An upregulation has been observed 
in response to various pathophysiological conditions, 
such as bacterial infection, inflammation, tumor-
flanking tissues, carcinogen exposure, etc. Expression 
has also been noted in other tissues such as the brain 
and in immune cells. 
Localisation 
Extracellular. DMBT1 is either secreted to the mucus 
and other body fluids or to the extracellular matrix. 
Function 
DMBT1 exerts at least two distinct functions. As 
extracellular matrix protein, DMBT1 triggers polarity 
and terminal differentiation of epithelial cells as well as 
differentiation of embryonic stem cells to monolayered 
epithelia, which has been demonstrated by in vitro 
studies with rodent orthologs of DMBT1. DMBT1 
secreted to the luminal side of epithelial surfaces plays 
a role in defense against bacterial and viral pathogens. 
This mechanism includes pathogen recognition through 
a peptide motif present in the SRCR domains and 
mediation of pathogen aggregation. DMBT1 further 
has been shown to exert anti-inflammatory effects. In 
response to activation of the intracellular pattern 
recognition molecule NOD2 and consecutive NFkB -
activation, upregulation of DMBT1 takes place, which 
in turn hinders bacterial invasion and LPS-induced 
TLR4 -activation. Hindrance of bacterial invasion may 
abolish NOD2 activation. Thus DMBT1 may act anti-
inflammatory via inhibiting both NOD2- and TLR4-
mediated NF-kB-activation. As DMBT1 is NF-kB 
responsive, this presumably builds up an autoregulatory 
homeostatic loop, by which DMBT1 is able to regulate 
its own expression as extracellular sensory element. 
These data point to a function in anti-inflammatory 
immune exclusion similar to mucosal antibodies 
(sIgA). 
Homology 
Homologies exist to other SRCR proteins such as CD5
and CD6, which function in immune defense. However, 
to date there is no SRCR protein known that 
additionally contains CUB and ZP domains. At the 
level of the SRCR domains, DMBT1 further shares 
some homologies with the sponge aggregation receptor 
(AR), which initiates the first steps in regeneration of a 
complete sponge body after dissociation. 
Mutations 
Germinal 
Initial evidence has been gained that the SRCR- and 
SID-coding exons are subjected to copy number 
variations. 
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Somatic 
Few point mutations have been identified in cancer so 
far. There is no hard evidence for an inactivation by 
biallelic mutation in cancer. Copy number variations of 
the SRCR- and SID-coding exons have been noted in 
different cancer types, including brain, lung, breast, 
gastrointestinal tumors and melanoma. It has not yet 
been determined to which extent these represent de 
novo rearrangements or germline 
mutations/polymorphisms. Underexpression has been 
observed for lung, colon, gastric, esophageal, breast, 
and skin cancer. By contrast overexpression was 




Based on underexpression and on its role in triggern  
differentiation, a role in tumor suppression of different 
cancer types, mainly of epithelial origin, has been 
proposed. A genetic scan in mice identified DMBT1 as 
candidate genetic modifier, which may determine the 
penetrance of breast cancer in the presence of p53 
mutations. Lower DMBT1 protein levels have been 
observed in the normal mammary gland epithelium of 
women, which developed breast cancer versus tissues 
obtained from healthy donors. 
Crohn's disease 
Disease 
Activation of DMBT1 was found to be impaired in the 
intestinal epithelium of Crohn's disease with 
predisposing NOD2 mutations. 
Infection 
Disease 
Based on its broad bacterial binding specificity and 
inhibitory effects on bacterial and viral (HIV, influenza 
A viruses) infection in vitro, a role in infectious 
diseases has been proposed. 
Caries 
Disease 
DMBT1 alias SAG (salivary agglutinin) has been 
studied for about two decades as the major caries 
bacteria agglutinating non-immunoglobulin in the 
saliva/oral cavity. Based on its capacity to aggregat  
caries bacteria (e.g. Streptococcus mutans), it was
proposed to exert functions in preventing caries. Based 
on its capacity to mediate bacterial adhesion to enamel-
like surfaces, it was proposed to exert functions i 
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